CA
NZ
UK
AU
IND
US
IN8bio posted a loss per share for the most recent quarter that was less severe than analysts had forecast. The company’s stock price has been on a pronounced downtrend throughout the year, underscoring persistent investor concern despite the earnings improvement. This narrowing of the …
AIM ImmunoTech Inc. has secured a $1.5 million manufacturing agreement with Sterling Pharma Solutions, enhancing efforts to produce essential drug substances for its pipeline, notably Ampligen. This arrangement will facilitate the manufacture of polynucleotide substances, PolyI and Poly C12U, key for ongoing clinical trials, …
This performance underscores Apyx Medical's potential in the evolving surgical aesthetics market, positioning it as a viable option for investors aiming to capitalize on trends in this field.
The additional resources are slated for advancing the AlloNK platform and supporting a Phase 3 registrational study scheduled for later this year.
This figure surpasses the previous quarter’s performance, showcasing the company’s increasing market share, primarily driven by strong demand for its key products, IBSRELA and XPHOZAH. Comparatively, Ardelyx reported an earnings per share (EPS) of $-0.07 for this quarter against a consensus estimate of $-0.06. …
Beyond Air, Inc. (NASDAQ: XAIR) executed a 1-for-20 reverse stock split on July 13, 2026, successfully raising its common stock price to above the $1 per share threshold required by Nasdaq. This action was essential for maintaining the company’s listing, as it had received …
Collegium Pharmaceutical has achieved a key milestone by completing the acquisition of AZSTARYS, a move expected to enhance its dominance in the ADHD treatment market. This acquisition supports Collegium's existing product lineup while positioning it for a broader market share in a segment with …
Cytosorbents Corporation's (NASDAQ: CTSO) second-quarter revenue remained flat at $9.6 million compared to the previous year. Analysts had anticipated a slightly better performance, estimating earnings per share of $-0.05, while the actual result showed a net loss of $4.4 million, translating to $0.07 per …
Leef Brands Inc. secured $9.3 million in an oversubscribed financing round, bolstering its balance sheet and providing capacity for future expansions. This strategic move enhances investor confidence, as it positions the company for growth through new acquisitions and market opportunities.Key HighlightsLeef Brands completed an …
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) reported earnings per share (EPS) of $0.91 for the second quarter, a result that comfortably topped the consensus estimate. This performance reflects growing confidence in Amphastar's ability to deliver solid financial results amid a volatile market. With a market …
Please wait processing your request...